3-generation family medical histories of mental, neurologic, cardiometabolic, birth defect, asthma, allergy, and autoimmune conditions associated with autism

Diana Schendel, PhD	**1, 2, 3**
Linda Ejlskov, PhD	**2, 3**
Morten Overgaard, PhD	**4**
Zeal Jinwala	**1, 5**
Viktor Kim	**1**
Erik Parner, PhD	**4**
Amy E Kalkbrenner, PhD	**6**
Christine Ladd Acosta, PhD	**7**
M Danielle Fallin, PhD	**8, 9, 14***
Sherlly Xie, PhD	**10, 11**
Preben Bo Mortensen, DrMedSci	**2, 3, 12**
Brian K Lee, PhD	**1, 10, 13**

1. A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA, USA
2. The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark
3. National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark
4. Department of Public Health, Aarhus University, Aarhus, Denmark
5. School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA
6. University of Wisconsin Milwaukee, Joseph J Zilber College of Public Health, Milwaukee, WI, USA
7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
8. Wendy Klag Center for Autism and Developmental Disabilities, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
9. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10. Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA
11. Medtronic, Mounds View, Minnesota, USA
12. Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark
13. Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
14. Current affiliation: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA

Corresponding author: Diana Schendel, A.J. Drexel Autism Institute, Drexel University, 3020 Market Street, Suite 560, Philadelphia, PA, USA. Email: des348@drexel.edu Ph: +1 770-317-3008

Abstract

Background: Family histories of different mental and non-mental conditions have often been associated with autism spectrum disorder (ASD) but the restricted scope of conditions and family members that have been investigated limits etiologic understanding. We aimed to perform a comprehensive assessment of ASD

associations with 3-generation family histories of 90 mental, neurologic, cardiometabolic, birth defect, asthma, allergy, and autoimmune conditions. The assessment comprised separate estimates of association with ASD overall; separate estimates by sex and intellectual disability (ID) status; as well as separate estimates of the co-occurrence of each of the 90 disorders in autistic persons. Additionally, we aimed to provide interactive catalogues of results to facilitate results visualization and further hypothesis-generation.

Methods: We conducted a population-based, registry cohort study comprised of all live births in Denmark, 1980-2012, of Denmark-born parents, and with birth registry information (1,697,231 births), and their 3-generation family member types (20 types). All cohort members were followed from birth through April 10, 2017 for an ASD diagnosis. All participants (cohort members and each family member) were followed from birth through April 10, 2017 for each of 90 diagnoses, emigration or death. Adjusted hazard ratios (aHR) were estimated for ASD overall; by sex; or accounting for ID via separate Cox regression models for each diagnosis-family member type combination, adjusting for birth year, sex, birth weight, gestational age, parental ages at birth, and number of family member types of index person. aHRs were also calculated for sex-specific co-occurrence of each disorder, for ASD overall and considering ID. A catalogue of all results is displayed via interactive heat maps here: https://ncrr-au.shinyapps.io/asd-riskatlas/ and interactive graphic summaries of results are here: https://public.tableau.com/views/ASDPlots_16918786403110/e-Figure5 .

Results: Increased aHRs for ASD (26,840 cases; 1.6% of births) were observed for almost all individual mental disorder-family member type combinations yet for fewer non-mental disorder-family member type combinations. aHRs declined with diminishing degree of relatedness between the index person and family member for some disorders, especially mental disorders. Variation in aHR magnitude by family member sex (e.g., higher maternal than paternal aHRs) or side of the family (e.g., higher maternal versus paternal half sibling aHRs) was more evident among non-mental than mental disorders. Co-occurring ID in the family member or the index person impacted aHR variation.

Conclusion: Our approach revealed considerable breadth and variation in magnitude of familial health history associations with ASD by type of condition, sex of the affected family member, side of the family, sex of the index person, and ID status which is indicative of diverse genetic, familial, and non-genetic ASD etiologic pathways. More careful attention to identifying sources of autism likelihood encompassed in family medical history, in addition to genetics, may accelerate understanding of factors underlying neurodiversity.

Introduction

Strong familial aggregation of autism spectrum disorder (ASD)[1-7] was an early clue to ASD etiology, suggesting a genetic influence. Early genetic studies focusing on specific autism candidate genes yielded limited understanding of ASD genetic architecture whereas such knowledge rose markedly following comprehensive scans in genome-wide association studies (GWAS) in large samples. From GWAS we can now estimate individual genetic liability for ASD using a polygenic score (PGS).[8] GWAS results of genetic overlap between ASD and other psychiatric, cognitive and behavioral phenotypes[8, 9] also provide valuable etiologic clues. Finally, open source sharing of GWAS summary statistics for use in other studies or for large meta-analyses has stimulated further hypothesis testing and enhanced research capacity into ASD.

Similarly, more comprehensive understanding of family health history in ASD may accelerate understanding of the origins of neurodiversity and can complement genetic investigations, as has been shown for many diverse conditions.[10] For example, enhanced prediction of conditions such as coronary artery disease and schizophrenia has been achieved when accounting for both PGS and family history, over PGS alone.[11,12] Yet to date the investigation of family medical history in ASD is more fragmented when compared to advances in genetics. While significant ASD associations from family histories of mental or non-mental disorders are consistently reported,[13-26] the typical approach has been to focus on limited numbers of disorders or family members, e.g., parents, siblings – a kind of 'candidate family history' approach. Such an approach makes it difficult to assess ASD associations across disorders or family member types which may inform etiologic understanding or additional hypothesis-generation.

Our study goal was to advance a more comprehensive understanding of family medical history in ASD and facilitate future neurodiversity hypothesis-generation by: 1) estimating ASD associations with 90 mental and

non-mental diagnosis categories reported in family members across 3 generations in order to map variation in associations between ASD and specific conditions across 20 family member types distinguished by degree of relatedness, sex and maternal or paternal side of the family and 2) further identify specific features of the structure of familial medical history associations with autism by providing separate estimates of association per family member and per condition: for ASD overall, for ASD in females and males, and for the ASD with ID sub-phenotype. To complete the medical history profile and complement the family history associations, we also calculated co-occurrence estimates of the 90 disorders in autistic females and males, overall and in ASD with ID. Finally, to facilitate understanding and further hypothesis-generation, we developed open resources for our results (catalogue of individual results in interactive heat maps here https://ncrr-au.shinyapps.io/asd-riskatlas/ and interactive graphic results summaries here: https://public.tableau.com/views/ASDPlots_16918786403110/e-Figure5 .

Methods

We followed STROBE guidelines for our study reporting.[27]

The study cohort (e-Figure 1) comprised all live births born in Denmark, 1 January 1980 through 31 December 2012, with a valid personal identification number, of known parents who themselves were born in Denmark, and with Medical Birth Register[28] information (N= 1,697,231; 82.2% of births). We chose to identify twenty, 3-generation family member types (family members of 1st, 2nd, and 3rd degrees of relatedness with the index birth distinguished by sex and side of the family; e-Figure 2) for each study cohort member via linkage with the Danish Civil Registration Service[29] (e-Tables 1-2, e-Figure 3).

The mental, neurologic, cardiometabolic, birth defect, autoimmune, asthma, and allergy diagnosis categories, and including all associated individual diagnoses within each category, were selected for study based on previously reported associations with ASD of one or more specific diagnoses within a category.[13-26] All diagnoses (e-Table 3) were obtained via linkage with the Psychiatric Central Research and National Patient Registers.[30, 31]

Child sex, date of birth, birth weight, gestational age, parental ages at birth, death and emigration information was obtained from the Medical Birth Register and Civil Registration Service. There were no missing data since, by design, the very small proportions of cohort members with missing mother (0.2%), father (0.9%), or birth registry information (0.12%) were excluded (eFigure 1).

All persons were followed through April 10, 2017 (cohort members: 5.25 years minimum and 37.25 years maximum follow-up time; family members born before 1980: 37.25 years minimum and 40.25 years maximum follow-up time) for medical diagnoses, emigration or death, whichever came first. If more than one sibling, aunt, uncle or cousin had received a specific diagnosis (e.g., two full siblings received an ADHD diagnosis), the earliest diagnosis date was chosen for analysis. For each of the 20 family member types, separate Cox regression models were fitted for each diagnosis. The adjusted hazard ratio (aHR) for ASD was estimated using separate baseline ASD diagnostic rates for each 1-year stratum of birth year, adjusting for sex, birth weight ($\leq$2500g, 2501-3000g, 3001-4000g, 4001+g), gestational age ($\leq$36 weeks, 37-40 weeks, 41+weeks) and parental ages at birth ($\leq$35 years, 36+ years). Models for estimates from full/half siblings, aunts, uncles or cousins also included the number of family members of the relevant type as a covariate. From grandparents, parents, aunts and uncles the diagnosis exposure was based on the family member's reported diagnosis status (Yes/No per diagnosis) at birth of the index child. For index persons, full/half siblings and cousins the diagnosis exposure

was time varying and based on the date of the diagnosis with robust standard errors clustered on the personal identifier of the index child. Separate aHRs were calculated for i) ASD overall, ii) for ASD in females and males and iii) for the subphenotype ASD with ID.

As part of the family history profile per diagnosis, in addition to aHRs of the associations between family health conditions and ASD in the index person, aHRs were also calculated for co-occurrence of each condition in autistic females and males, as well as for autistic persons with ID. aHRs for a co-occurring condition associated with ASD was based on whether ASD had, or had not, been reported for the index person prior to the co-occurring condition.

Sensitivity analyses were carried out to assess the effects of co-occurring ID in family members with a specific health condition on the association between the family health condition and ASD in the index person. These analyses included ID status of the exposing family member as an additional potential confounder variable in models. Similarly, ID status of the autistic person was included as an additional potential confounder variable in separate models to estimate aHRs for disorder co-occurrence in ASD.

No aHR was estimated in any analysis if there were <5 ASD exposed cases per family member type-diagnosis combination or with a co-occurring condition.

This study was approved by the Danish Data Protection Agency and the Danish Health Data Authority. According to Danish law, this secondary use of register data (collected for clinical or administrative purposes), where researchers only have access to pseudo-anonymized information, does not require informed consent.

Data Availability

The individual-level data that support the findings of this study are available from Statistics Denmark. The individual level data can only be accessed through Statistics Denmark secure servers where downloading individual level information is prohibited. Access to individual-level data in Denmark is governed by the Danish authorities, including the Danish Data Protection Agency, the Danish Health Data Authority, the Ethical Committee, Statistics Denmark and the Danish National Archives. Each scientific project must be approved before initiation and approval is granted to a specific Danish research institution. Researchers at Danish research institutions may obtain the relevant approval and data. International researchers may gain data access if governed by a Danish research institution with the required approval and data access. Data access requires the completion of a detailed application form from the Danish National Board of Health, and Statistics Denmark. For more information on accessing the data, see https://www.dst.dk/en.

Since the downloading of individual-level data from Statistics Denmark secure servers is prohibited, for purposes of data availability for this study we obtained approved exports of the necessary summary data needed to generate each aHR and the corresponding 95% confidence interval reported in the study results tables and figures. These data files are fully accessible here on the RShiny platform: https://ncrr-au.shinyapps.io/asd-riskatlas/. In addition, we prepared a repository on GitHub (https://github.com/ASDepiteam/ATLAScode) for the data and code used to generate the study's RShiny webpage which describes the study design and interactive heatmaps of results (adjusted hazard ratios (aHR) calculated via Cox regression models). The data management scripts in the repository incorporate the study's exported summary data needed to generate each aHR (and corresponding 95% confidence interval) reported in the study results tables, figures and heatmaps. The app.R file is the master file that is used to build and design

the interactive features of the RShiny webpage, incorporating the data management scripts to include tables and figures on the webpage.

Results

Autistic persons (1.6% of cohort) were more likely than non-autistic persons to have ID, be male, have a gestational age below 37 weeks, birth weight below 2500g or above 4000g and parents above 35 years of age at birth. The cohort birth year distribution of autistic persons varied, peaking at 6.2% of all ASD cases identified among births in 2000 (Table 1).

We observed increased aHRs for ASD associated with specific diagnosis across all diagnosis categories. Foremost, we observed increased aHRs associated with every mental disorder in family members of all degrees of relatedness in contrast to the more limited frequency of elevated associations among family members with non-mental disorders (neurologic, cardiometabolic, birth defect, autoimmune, asthma, and allergy conditions; Figure 1 - heat map of aHRs by diagnosis and family member type; Figure 2 - summary plots of % of aHRs at different levels of magnitude by disorder category and degree of family relatedness). Further, 70-99% of the ASD aHRs from mental disorders across all family member types were statistically significant (aHR confidence interval excluded 1.0) while this was less frequently true of the estimates from non-mental disorders (5%-60%, typically 35% or fewer per condition category; Figure 3; e-Figure 4). A family history of ASD posed the largest aHR of all: a 4- to 7-fold risk for ASD in the index person associated with ASD diagnosed in 1st degree relatives (mother, father, full brother, full sister; Figure 4). There were also 3- to 4-fold risks associated with a 1st degree relative diagnosed with ADHD, ID, other developmental disorders, organic mental disorders, tic disorders, schizophrenia or pernicious anemia (Figure 4), as well as with a maternal grandmother or paternal grandfather

diagnosed with other developmental disorders (maternal grandmother aHR: 4.34; paternal grandfather aHR: 3.76) or a maternal half-sister diagnosed with tic disorders (aHR: 4.10). All other aHRs across all other individual diagnoses across all family member types fell below a 3-fold elevation (aHRs < 3.0; Figure 1).

For some diagnoses we observed a pattern of declining ASD risk with decreasing degree of relatedness between the index person and an affected family member (i.e., per diagnosis, highest aHR in 1st degree relatives and declining to lowest in 3rd degree relatives). This pattern was most common with different mental disorders while with non-mental disorders it was less common and with less marked a decline (e.g., epilepsy, obesity) or absent (different birth defects or autoimmune disorders) (Figure 5).

When considering ASD associations by sex of the family member with a disorder, or whether the family member was on the maternal or paternal side of the family, these factors (sex of the family member or side of the family) had a somewhat more marked effect on patterns of ASD associations from family members with non-mental than mental disorders. For example, for mental disorders, the proportions of aHRs at different levels (e.g., % of aHRs >= 1.10, >=1.40 or >=1.70), or proportions of aHRs that were statistically significant (% of aHRs where confidence interval excluded 1.0), were very similar across mental disorders in different 1st degree relatives regardless of sex of the family member (e-Figures 5-8). Among non-mental disorders, however, the proportions of aHRs at different levels, or proportions of aHRs that were statistically significant, were higher with an affected mother than father (e-Figures 5-6) and these proportions varied also among full siblings by sex (e.g., from brothers with any type of autoimmune disorder there were no aHRs >= 1.40, or no statistically significant aHRs compared to estimates from affected sisters where 11% of aHRs >= 1.40, 5% of aHRs >= 1.70 and 35% of aHRs with confidence intervals excluding 1.0; e-Figures 7-8) and among half siblings by side of the family (e.g., higher proportions from affected half siblings on the maternal than paternal side of the family with

neurologic, birth defect or autoimmune disorders) (e-Figures 9-10). Levels of aHRs from cardiometabolic conditions in grandparents of both sexes and sides of the family were primarily in the range of aHRs 1.10-1.39 (e-Figures 11 and 13) and over 70% of these estimates were also statistically significant (aHR confidence interval excluded 1.0; e-Figures 12 and 14). For birth defects, the proportions of ASD risks at different levels of magnitude (e.g., % of aHRs >1.10, >1.40 or >1.70) or of estimates that were statistically significant (aHR confidence interval excluded 1.0) were somewhat higher on the maternal than paternal side of the family and in female more than male family members (e-Figures 15-18). For asthma, specifically, all ASD aHRs fell below aHR 1.40 but the proportions of all estimates that fell in the range of aHR 1.10-1.39 were higher with affected family members on the maternal side of the family (50% versus 30% on paternal side) or were female (60% versus 30% among males) as were the proportions of estimates that were statistically significant (50% on maternal side versus 20% on paternal side; 60% in female family members versus 30% in males).

When considering differences by sex of the index person of family history associations for ASD by estimating ASD associations in males and females separately, there were somewhat fewer estimates that could be calculated compared to ASD overall, partly due to smaller sample sizes when stratifying by sex of the index person, especially among females (e-Figures 19 and 20 compared to Figure 1). However, two patterns observed for ASD overall persisted in sex-specific analysis. First, as in ASD overall, there was a preponderance of elevated ASD aHRs in both males and females from <u>mental</u> versus <u>non-mental disorders</u> in the family (i.e., larger proportions of risk estimates at each level of aHR from <u>mental</u> versus <u>non-mental</u> disorders in the family (e-Figure 21) and about 60%-70% of <u>mental disorder</u> estimates were statistically significant compared to about 30% or fewer of <u>non-mental disorder</u> estimates (e-Figure 22)). Second, as in ASD overall, with <u>non-mental disorders</u> the proportions of ASD aHRs in both males and females at different levels of magnitude, or proportions of estimates that were statistically significant, were higher with an affected mother than father

whereas these proportions were very similar between affected mothers and fathers with mental disorders (e-Figures 23-26).

The effects of ID on family medical history associations with ASD were examined in two ways: accounting for co-occurring ID in the family member when estimating the association between a disorder, e.g., diabetes, in the family member and ASD in the index person; and estimating aHRs for ASD with ID, specifically, in the index person associated with a disorder in a family member. When accounting for co-occurring ID in the family member, the magnitude of the aHR for ASD in the index person associated with medical diagnosis in the family member generally either remained the same or was attenuated compared to results when not accounting for ID (e-Figures 27-46) with one exception: adjustment for co-occurring ID in paternal half siblings actually INCREASED many aHRs for ASD associated with individual mental and non-mental disorders in paternal half siblings (e-Figures 33-34). Concerning patterns of association with ASD with ID in the index person, one notable difference in results was observed compared to patterns of association with ASD overall: regarding associations with ASD with ID in the index person from family history there was no preponderance of elevated associations with maternal neurologic, birth defect and autoimmune disorders (e-Figures 47-48) compared to paternal associations as seen in ASD overall (e-Figures 5-6).

To complete the family history profile, in addition to aHRs for ASD associated with a history of different family conditions, we also estimated aHRs for co-occurrence of the same conditions in autistic persons. There were increased aHRs for co-occurrence of every mental disorder in autistic males and females while increased aHRs of co-occurrence of non-mental disorders were less frequent (e-Figures 49-50). Across all disorders, however, when there were significant aHRs for the co-occurrence of a condition in both sexes, the aHR in autistic females was in most instances higher than in males (e-Figure 51). Finally, as can be seen in Figure 1 (where we included

the co-occurrence aHRs alongside the family medical history aHRs for ease of their comparison), an increased aHR for co-occurrence of a mental disorder diagnosis in autistic persons was observed in parallel with elevated risks for ASD from 1st degree (or 2nd or 3rd degree) family members with the same diagnosis. Such 'alignment' between significantly increased familial risk for ASD from a specific diagnosis and significantly increased ASD co-occurrence risk for the same diagnosis was evident across all mental disorders but less so among non-mental disorders (e.g., significantly elevated co-occurrence aHR for eye defects in autistic male or female index persons but no significantly elevated aHR for ASD in the index person from eye defects diagnosed in the family). In both mental and non-mental disorders, however, if a condition was associated with both a significantly elevated ASD aHR for co-occurrence and elevated familial aHRs, the co-occurrence aHR was generally higher in magnitude than the familial aHR (e-Figures 52-53).

We also examined the effects of ID on aHRs of co-occurrence of other conditions in autistic persons. The aHR of co-occurrence of a second specific diagnosis in persons with ASD typically was attenuated when accounting for co-occurring ID in the autistic person, especially in autistic females, compared to results not accounting for ID (e-Figures 54-55). When considering aHRs of co-occurrence focusing only on the subgroup of autistic persons with ID, there were fewer aHRs that could be calculated compared to ASD overall, partly due to smaller sample sizes of autistic persons with ID, especially among autistic females with ID (e-Figure 56 heat map for ASD with ID versus Figure 1 for ASD overall). Differences between co-occurrence aHRs by diagnosis in autistic males and females overall compared to autistic males and females with ID were quite variable: for some disorders the co-occurrence aHR was higher in autistic persons with ID (e.g., epilepsy, CNS birth defects, Type 2 diabetes) while in others the aHR was lower compared to ASD overall (e.g., most mental disorders) (e-Figures 57-58). Nevertheless, the higher female than male aHR for select co-occurring conditions seen in ASD overall persisted

in ASD with ID, including higher co-occurrence aHR for schizophrenia, epilepsy, Type 2 diabetes, and chromosomal defects in autistic females with ID than autistic males with ID (e-Figure 59).

Discussion

Our comprehensive approach revealed the considerable breadth and depth of the range of disorders in families associated with ASD occurrence. While many of our findings are consistent with the literature, the results also yielded new perspectives into sources and patterns of family medical history associated with ASD, lending insights into specific potential etiologic pathways to be explored in further studies designed for specific hypothesis-testing. We highlight some specific examples of this in the discussion that follows.

First, declining risk for ASD from a disorder in the family by declining genetic relatedness between the affected family member and the index person suggests genetic mechanisms linking ASD and the disorder. A genetic mechanism fits well with the marked decline in aHRs in our data for ASD in the index person by degree of relatedness in the family member with ASD, previous reports of significant sibling and cousin ASD recurrence risk,[3, 4, 6] and significant genetic risk in ASD.[8] A genetic mechanism is also consistent with our observed aHR gradients for ASD associated with ID, ADHD, schizophrenia and depression in families and reported genetic overlap between these conditions and ASD.[8, 9] Relatively weaker aHR gradients for ASD were associated with other mental disorders in the family, as well as with epilepsy, obesity or diabetes in the family, and no apparent gradient with birth defect, autoimmune, asthma or allergy conditions in the family. The weaker aHR gradients suggest weaker genetic overlap or other familial or non-genetic mechanisms linking these conditions in the family with ASD. For example, significant ASD aHRs associated with grandparents (of both sexes and sides of the family) with cardiometabolic conditions to our knowledge has not been previously reported and may

warrant further investigation of the potential for shared genetic liability between these disorders and ASD or possibly adverse lifestyles shared across generations that influence non-genetic prenatal risks.[32, 33]

Second, non-genetic, adverse prenatal exposure mechanisms linking maternal conditions with ASD may be evident in our results. We observed greater frequency of significant aHRs for ASD in the index person associated with neurologic, cardiometabolic, birth defect or autoimmune disorders in mothers compared to fathers. We also observed greater frequency of elevated aHRs arising from maternal than paternal half-siblings with neurologic, birth defect or autoimmune disorders – maternal half siblings (sharing the same mother but not father) are more likely to share prenatal environmental factors, and possibly postnatal environments, than paternal half siblings. ASD, notably, may be only one of many developmental effects of a specific maternal condition. For example, besides increased ASD risk, maternal prenatal diabetes or obesity increases offspring risk for birth defects[34-36] and maternal prenatal autoimmune disease increases risk for adverse pregnancy and developmental outcomes.[37-40] Thus, the elevated aHRs for ASD in our data associated with a wide array of non-mental conditions in a mother, full sib or maternal half sib may reflect a wide profile of different offspring outcomes linked via diverse pathways to specific maternal prenatal conditions. This hypothesis could be tested in future family-based designs by examining diverse outcome patterns within sibships associated with specific maternal conditions.

Third, a greater likelihood of autoimmune disorders[41, 42] and adult asthma[43-45] to occur in females than males that has been reported in other studies may partly explain the relatively greater frequency of elevated ASD aHRs in our data arising from autoimmune disorders in mothers and sisters (versus fathers and brothers) or from asthma in female family members (mostly on the maternal side of the family) (i.e., these conditions, as 'exposures', are more common in females than males and thereby we may more likely detect an association in

female than male family members). With respect to asthma, however, the adult asthma preponderance in females seen in other studies may be limited to non-allergic asthma.[46] Thus, further study of whether the asthma in female family members and ASD associations observed here are centered on non-allergic asthma may render clues to potential shared pathogenic mechanisms (e.g., sex hormone or obesity effects)[46] linking asthma and ASD in the same family. In contrast to asthma or autoimmune disorders, birth defects are more common among males[47] yet we observed more frequent elevated ASD aHRs associated with birth defects in female family members or on the maternal side of the family – a sex-related difference which may warrant further scrutiny also.

We assessed patterns of influence of sex and ID in family medical history associations with ASD which we hypothesized might yield clues as to underlying mechanisms linking specific conditions, or types of conditions, and ASD. Considering these two factors (sex or ID), departures from the overall ASD results actually were most evident in the aHRs for ASD after accounting for the effects of co-occurring ID in a family member. The latter results (i.e., aHR for ASD from a disorder in a family member after accounting for co-occurring ID in the family member) most often involved attenuation of the aHR for ASD in the index person which is consistent with the hypothesis that genetic risk for autism may not be specific for autism alone, but also overlap other conditions such as ID.[48] That is, the aHR attenuation that we observed may indicate that the apparent elevated ASD aHR associated with the disorder in the affected family member was confounded by the co-occurrence of ID in the family member. Another ID effect on ASD risk was seen in the aHRS for the ASD with ID outcome: specifically, while there was a marked higher frequency of elevated aHRs for ASD overall associated with mothers versus fathers with neurologic, birth defect or autoimmune conditions, there were no such mother-father differences observed in the aHRs for ASD with ID. The latter pattern suggests that there may be prenatal influences of maternal neurologic, birth defect or autoimmune conditions on risk for ASD overall but not on ASD with ID,

specifically. There were also diagnosis-specific differences in aHRs for ASD with ID versus ASD overall, e.g., higher ASD with ID aHRs associated with maternal schizophrenia compared to the aHR for ASD overall – an ID-related difference which might warrant further investigation.

Both ID and sex effects were also evident in variation of the aHR estimates of disorder co-occurrence in autistic persons. That is, while our observed co-occurrence likelihoods in persons with ASD are consistent with previous studies[25, 26, 49-52], we further observed risk differences by sex (e.g., higher female co-occurrence risk across most conditions) and the impact of ID on ASD co-occurrence risk, especially in autistic females. Thus, our results yielded diverse views into the influence of sex or ID on family medical history risk for ASD and co-occurrence risk in ASD that may spur further inquiries into male-female ASD phenotype differences, the interplay between ID and ASD, and potential underlying risk mechanisms.

The strength of our approach was the systematic, population-based estimation of ASD associations from a single population and methodology across multiple disorder and family member type combinations. This approach, plus provision of an open, interactive display of estimates for each disorder-ASD association, provides important context for comparison, interpretation, and further hypothesis generation for future studies. We chose to not correct for multiple testing since our aims were to produce a data resource for hypothesis-generation and baseline comparison with other studies. Additionally, more complex modeling or confounder adjustment per condition was beyond the scope of the analysis and each result will need closer scrutiny. Some associations based on small sample sizes may be spurious. Since general practitioners do not report to Danish registries, our data are relevant to conditions diagnosed by specialists. Lastly, we focused on pathways not acting via factors impacting birth weight and gestational age.

Conclusion

Our investigation of family medical history in ASD revealed considerable breadth and variation in patterns of association suggestive of diverse genetic, familial and non-genetic ASD etiologic pathways. Family medical history serves as a complementary measure to genetic measures,[10] perhaps by encompassing unidentified genetic (e.g., not captured by current PGS) and non-genetic components, as seen in diabetes.[53] Thus, more careful attention to identifying mechanisms of autism likelihood encompassed in family medical history, in addition to genetics, may accelerate understanding of factors underlying neurodiversity. We hope these findings stimulate such hypothesis testing, aided by our open data resource.

Competing Interest Statement

The authors have no competing interests to declare.

Funding Acknowledgements

The study was supported by the Lundbeck Foundation (iPSYCH, Grant numbers R102-A9118 and R155-2014-1724), the National Institute of Environmental Health Sciences of the National Institutes of Health under Award No. R01ES026993, and the National Institute of Neurologic Disorders and Stroke of the National Institutes of Health under Award No. R01 NS131433. The funding sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Bailey, A., et al., *Autism as a strongly genetic disorder: evidence from a British twin study.* Psychol Med, 1995. **25**(1): p. 63-77.
2. Hallmayer, J., et al., *Genetic heritability and shared environmental factors among twin pairs with autism.* Arch Gen Psychiatry, 2011. **68**(11): p. 1095-102.
3. Gronborg, T.K., D.E. Schendel, and E.T. Parner, *Recurrence of autism spectrum disorders in full- and half-siblings and trends over time: a population-based cohort study.* JAMA Pediatr, 2013. **167**(10): p. 947-53.
4. Hansen, S.N., et al., *Recurrence Risk of Autism in Siblings and Cousins: A Multinational, Population-Based Study.* J Am Acad Child Adolesc Psychiatry, 2019. **58**(9): p. 866-875.
5. Lichtenstein, P., et al., *The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood.* Am J Psychiatry, 2010. **167**(11): p. 1357-63.
6. Sandin, S., et al., *The familial risk of autism.* Jama, 2014. **311**(17): p. 1770-7.
7. Steffenburg, S., et al., *A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden.* J Child Psychol Psychiatry, 1989. **30**(3): p. 405-16.
8. Grove, J., et al., *Identification of common genetic risk variants for autism spectrum disorder.* Nat Genet, 2019. **51**(3): p. 431-444.
9. Anttila, V., et al., *Analysis of shared heritability in common disorders of the brain.* Science, 2018. **360**(6395).
10. Mars N., et el*., Systematic comparison of family history and polygenic risk across 24 common diseases.* Am J Hum Genet. 2022 Dec 1;109(12):2152-2162.
11. Tada, H., et al., *Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history.* Eur Heart J, 2016. **37**(6): p. 561-7.
12. Lu, Y., et al., *Genetic risk scores and family history as predictors of schizophrenia in Nordic registers.* Psychol Med, 2017: p. 1-9.
13. Christensen, J., et al., *Risk of epilepsy and autism in full and half siblings-A population-based cohort study.* Epilepsia, 2016. **57**(12): p. 2011-2018.
14. Croen, L.A., et al., *Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study.* Arch Pediatr Adolesc Med, 2005. **159**(2): p. 151-7.
15. Atladottir, H.O., et al., *Association of family history of autoimmune diseases and autism spectrum disorders.* Pediatrics, 2009. **124**(2): p. 687-94.
16. Daniels, J.L., et al., *Parental psychiatric disorders associated with autism spectrum disorders in the offspring.* Pediatrics, 2008. **121**(5): p. e1357-62.
17. Jokiranta, E., et al., *Parental psychiatric disorders and autism spectrum disorders.* Psychiatry Res, 2013. **207**(3): p. 203-11.
18. Li, Y.M., et al., *Association Between Maternal Obesity and Autism Spectrum Disorder in Offspring: A Meta-analysis.* J Autism Dev Disord, 2016. **46**(1): p. 95-102.
19. Wu, S., et al., *Family history of autoimmune diseases is associated with an increased risk of autism in children: A systematic review and meta-analysis.* Neurosci Biobehav Rev, 2015. **55**: p. 322-32.
20. Xiang, A.H., et al., *Association of maternal diabetes with autism in offspring.* Jama, 2015. **313**(14): p. 1425-34.

21. Xie, S., et al., *Family History of Mental and Neurological Disorders and Risk of Autism.* JAMA Netw Open, 2019. **2**(3): p. e190154.
22. Sullivan, P.F., et al., *Family history of schizophrenia and bipolar disorder as risk factors for autism.* Arch Gen Psychiatry, 2012. **69**(11): p. 1099-1103.
23. Suren, P., et al., *Parental obesity and risk of autism spectrum disorder.* Pediatrics, 2014. **133**(5): p. e1128-38.
24. Wier M.L., Yoshida C.K., Odouli R., Grether J.K., Croen L.A., *Congenital anomalies associated with autism sprectrum disorders.* Dev Med Child Neurol 48:500-507.
25. Schendel D.E., Autry A., Wines R., Moore C., *The co-occurrence of autism and birth defects: prevalence and risk in a population-based cohort.* Dev Med Child Neurol 51: 779-786.
26. Christensen D., Van Naarden Braun K., Doernberg N.S., Maenner M.J., Arneson C.L., Durkin M.S., et al., *Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motot functioning – Autism and Developmental Disabilities Monitoring Network USA, 2008.* Dev Med Child Neurol 56:59-65.
27. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P.; STROBE Initiative. *The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.* Epidemiology. 2007 Nov;18(6):800-4.
28. Knudsen, L.B. and J. Olsen, *The Danish Medical Birth Registry.* Dan Med Bull, 1998. **45**(3): p. 320-3.
29. Pedersen, C.B., *The Danish Civil Registration System.* Scand J Public Health, 2011. **39**(7 Suppl): p. 22-5.
30. Mors, O., G.P. Perto, and P.B. Mortensen, *The Danish Psychiatric Central Research Register.* Scand J Public Health, 2011. **39**(7 Suppl): p. 54-7.
31. Lynge, E., J.L. Sandegaard, and M. Rebolj, *The Danish National Patient Register.* Scand J Public Health, 2011. **39**(7 Suppl): p. 30-3.
32. Klijs, B., et al., *The role of life-course socioeconomic and lifestyle factors in the intergenerational transmission of the metabolic syndrome: results from the LifeLines Cohort Study.* Int J Epidemiol, 2016. **45**(4): p. 1236-1246.
33. Nielsen, L.A., T.R. Nielsen, and J.C. Holm, *The Impact of Familial Predisposition to Obesity and Cardiovascular Disease on Childhood Obesity.* Obes Facts, 2015. **8**(5): p. 319-28.
34. Stothard, K.J., et al., *Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis.* Jama, 2009. **301**(6): p. 636-50.
35. Bell, R., et al., *Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study.* Diabetologia, 2012.
36. Brite, J., et al., *Maternal overweight and obesity and risk of congenital heart defects in offspring.* Int J Obes (Lond), 2014. **38**(6): p. 878-82.
37. Ornoy, A., et al., *Maternal autoimmune diseases and immunologically induced embryonic and fetoplacental damage.* Birth Defects Res A Clin Mol Teratol, 2004. **70**(6): p. 371-81.
38. Carp, H.J., C. Selmi, and Y. Shoenfeld, *The autoimmune bases of infertility and pregnancy loss.* J Autoimmun, 2012. **38**(2-3): p. J266-74.
39. Tersigni, C., et al., *Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms.* Hum Reprod Update, 2014. **20**(4): p. 582-93.
40. Twig, G., et al., *Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity.* J Autoimmun, 2012. **38**(2-3): p. J275-81.
41. Whitacre, C.C., *Sex differences in autoimmune disease.* Nat Immunol, 2001. **2**(9): p. 777-80.
42. Ngo, S.T., F.J. Steyn, and P.A. McCombe, *Gender differences in autoimmune disease.* Front Neuroendocrinol, 2014. **35**(3): p. 347-69.
43. Postma, D.S., *Gender differences in asthma development and progression.* Gend Med, 2007. **4 Suppl B**: p. S133-46.

44. Pignataro, F.S., et al., *Asthma and gender: The female lung.* Pharmacol Res, 2017. **119**: p. 384-390.
45. Jensen-Jarolim, E. and E. Untersmayr, *Gender-medicine aspects in allergology.* Allergy, 2008. **63**(5): p. 610-5.
46. Leynaert, B., et al., *Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort.* Thorax, 2012. **67**(7): p. 625-31.
47. Lary, J.M. and L.J. Paulozzi, *Sex differences in the prevalence of human birth defects: a population-based study.* Teratology, 2001. **64**(5): p. 237-51.
48. Myers SM, Challman TD, Bernier R, Bourgeron T, Chung WK, Constantino JN, Eichler EE, Jacquemont S, Miller DT, Mitchell KJ, Zoghbi HY, Martin CL, Ledbetter DH. Insufficient Evidence for "Autism-Specific" Genes. Am J Hum Genet. 2020 May 7;106(5):587-595.
49. Plana-Ripoll, O., et al., *Exploring Comorbidity Within Mental Disorders Among a Danish National Population.* JAMA Psychiatry, 2019. **76**(3): p. 259-270.
50. Croen, L.A., et al., *The health status of adults on the autism spectrum.* Autism, 2015. **19**(7): p. 814-23.
51. Kohane, I.S., et al., *The co-morbidity burden of children and young adults with autism spectrum disorders.* PLoS One, 2012. **7**(4): p. e33224.
52. Spann, M.N., et al., *Proband and Familial Autoimmune Diseases Are Associated With Proband Diagnosis of Autism Spectrum Disorders.* J Am Acad Child Adolesc Psychiatry, 2019. **58**(5): p. 496-505.
53. Cornelis, M.C., et al., *Genetic and environmental components of family history in type 2 diabetes.* Hum Genet, 2015. **134**(2): p. 259-67.

Figure 1. Hazard Ratio[a] for ASD from family morbidity by diagnosis and family member type

	Co-occur		1st degree				2nd degree								3rd degree				
	Index child (f)	Index child (m)	Sister	Brother	Mother	Father	Mat. half sister	Mat. half brother	Pat. half sister	Pat. half brother	Mat. grandmother	Mat. grandfather	Pat. grandmother	Pat. grandfather	Mat. aunt	Mat. uncle	Pat. aunt	Pat. uncle	Mat. cousin (f)	Mat. cousin (m)	Pat. cousin (f)	Pat. cousin (m)	
Mental			6.94*	6.48*	4.06*	6.57*	2.75*	3.31*	2.43*	2.02*					1.29	2.33*	2.75*	1.29	2.09*	1.77*	1.69*	1.56*	ASD
	13.64*	7.94*	3.62*	3.27*	2.85*	1.63*	1.71*	1.60*	1.36	1.38*	4.34*			3.76*	2.23*	1.48*	1.41	1.70*	1.58*	1.54*	1.36*	1.52*	Psych dev dis−not ASD
	7.74*	5.14*	3.32*	3.25*	4.01*	3.02*	1.75*	1.61*	1.61*	1.46*					1.52	2.03*	2.58*	2.15*	1.45*	1.59*	1.48*	1.44*	ADHD
	8.44*	6.11*	3.09*	3.12*	2.23*	2.25*	1.58*	1.53*	1.48*	1.49*	1.44	1.31	1.37	1.42	1.83*	1.98*	1.85*	1.45*	1.50*	1.50*	1.42*	1.46*	Behav dis−child onset
	17.49*	4.22*	3.04*	2.81*	1.51*	2.00*		1.98*	2.05*	1.81*	1.18*	1.25*	1.16*	1.25*	1.32	1.64*	1.51*	1.38*	1.85*	1.32	1.09	1.52*	Organic mental
			2.74*	3.40*	1.99*	1.82*	1.45*	1.67*	1.38*	1.35*	1.30*	1.27*	1.18*	1.23*	1.37*	1.43*	1.28*	1.31*	1.42*	1.50*	1.29*	1.41*	**Any mental**
	2.79*	2.43*	2.71*	2.30*	2.33*	2.07*	1.34*	1.65*	1.41*	1.31*	1.34*	1.38*	1.27*	1.23*	1.43*	1.44*	1.34*	1.43*	1.44*	1.51*	1.33*	1.49*	Adult personality disorder
	4.67*	3.06*	2.65*	2.72*	1.73*	1.13	1.34	2.59*	1.78*	1.12	1.11	1.17	1.20*	1.27*	1.49*	0.69	0.97	0.75	1.22	1.48	0.97	1.45	Bipolar disorder
	4.00*	3.99*	2.58*	2.30*	2.34*	2.47*	1.43*	2.01*	1.52*	1.39*	1.74*	1.10	1.30	1.74*	1.16	1.66*	1.76*	1.84*	1.27*	1.36*	1.19	1.39*	Mental−unspecified
	7.57*	5.09*	2.56*	2.47*	2.66*	1.77*	1.54*	1.85*	1.21	1.32*	1.29*	1.25*	1.19*	1.19*	1.33*	1.40*	1.24*	1.27*	1.50*	1.39*	1.34*	1.35*	Schizophrenia spectrum
	19.18*	11.97*	2.51*	3.01*	3.11*	3.02*	1.52*	1.63*	1.40	1.69*	1.85*	1.40*	1.43*	1.71*	1.13	1.29	1.57*	1.59*	1.45*	1.48*	1.30*	1.33*	Intellectual disability
	3.35*	3.42*	2.45*	2.92*	2.03*	1.72*	1.22*	1.79*	1.32*	1.12	1.16*	1.10	1.05	1.19*	1.29*	1.20*	1.22*	1.09	1.35*	1.27*	1.28*	1.46*	Any mood
	7.91*	4.85*	2.45*	2.26*	3.35*	2.37*	1.55*	1.91*	1.68*	1.05	1.26*	1.23	1.17	1.63*	1.56*	1.34*	1.25	1.24*	1.55*	1.25	1.44*	1.38*	Schizophrenia
	13.65*	7.80*	2.42*	3.21*			4.10*	1.72*		2.55*						2.62*			0.91	1.70*	1.23	1.52*	Tic disorder
	3.18*	3.41*	2.37*	2.96*	2.11*	1.77*	1.23*	1.82*	1.27*	1.06	1.23*	1.15*	1.12*	1.13*	1.20*	1.29*	1.26*	1.15	1.37*	1.27*	1.31*	1.50*	Depression
	4.18*	3.69*	2.30*	2.36*	1.87*	1.75*	1.28*	1.40*	1.33*	1.17	1.37*	1.27*	1.18*	1.24*	1.36*	1.46*	1.25*	1.20*	1.35*	1.32*	1.24*	1.31*	Neurotic/stress disorder
	2.63*	2.00*	1.86*	1.68*	1.86*	1.65*	1.23	1.06	1.18	1.26*	1.21*	1.27*	1.26*	1.28*	1.18	1.18*	1.61*	1.27*	1.37*	1.30*	1.29*	1.36*	Psychoactive sub use
	3.00*	6.52*	1.68*	2.27*	1.65*	1.82*	1.47*		1.27	1.47	1.33	1.38	1.54	1.55	1.28*	1.60*	0.97	0.84	1.19*	1.46*	1.10	0.97	Behav synd−physiol
	3.02*	4.02*	1.65*		1.76*		1.60		1.24		1.23		1.07		1.28		0.82		1.14	1.07	0.88	0.95	Anorexia nervosa
	4.97*	5.58*	1.61*	2.56*	1.87*	2.11*	1.02	1.41	1.32	1.05	1.11	1.25	0.78	1.26	1.47	1.10	0.66	1.52	1.36*	1.21	1.39*	1.21	OCD
Neurologic	3.37*	2.42*	2.02*	1.01	2.60*	1.20	1.39			1.56	0.95	1.15	1.14	0.92	1.08	1.32	0.93	1.12	1.23	1.12	1.37	0.97	Extrapyramid
		2.02	1.42		2.30*						1.00	1.28	0.67	1.27					0.91		1.49	0.82	Systemic atrophies
	2.40*	2.24*	1.36*	1.43*	1.49*	1.41*	1.38*	1.20*	1.16	1.08	1.24*	1.09*	1.14*	1.04	1.14*	1.06	1.15*	1.06	1.01	1.20*	1.08*	1.12*	Episodic
	5.27*	4.08*	1.35*	1.40*	1.62*	1.55*	1.38*	1.27*	1.24	1.13	1.15*	1.16*	1.11	1.15*	1.20*	1.09	1.18*	1.15*	1.04	1.28*	1.08	1.09	Epilepsy
	2.21*	2.04*	1.33*	1.33*	1.40*	1.29*	1.30*	1.21*	1.11	1.04	1.12*	1.12*	1.06*	1.04	1.13*	1.12*	1.12*	1.09*	1.05	1.17*	1.13*	1.06*	**Any neurologic**
	1.21	0.85	1.29*	1.20	1.16*	1.09	1.11	0.93	1.06	1.12	1.08*	1.14*	0.98	1.02	1.03	1.05	1.06	0.96	1.17	1.10	1.20*	1.04	Nerve disorder
	7.84*	4.31*	1.27	1.20	1.52*	1.34	0.79	1.30	0.66	1.01	1.34	0.94	1.41*	0.77	0.86	1.15	1.16	0.92	0.95	1.12	1.20	0.97	Cerebral palsy
	3.18*	2.42*	1.20	1.35*	1.65*	1.19	1.25	1.13	1.11	0.86	1.18	1.29*	1.04	1.05	1.29	1.46*	0.92	1.41*	1.16	1.21*	1.23*	1.14	Other neurologic
	1.43	1.45*	1.20	0.95	1.17	1.13	1.26	1.03	0.94	1.09	0.72	1.04	1.06	0.91	1.28	1.16	0.92	1.39*	1.19	1.36*	1.18	0.85	Inflammatory of CNS
		1.52	1.17		1.34*	1.12		2.91*	1.19	1.59	0.98	0.99	1.13	0.95	1.07	0.88	1.02	1.24	0.67		1.18	1.14	Demyelinating of CNS
	3.35*	1.38	1.17	0.80	1.46	1.33					1.07	1.12	1.11	0.93	1.13	1.32	1.07	0.60	1.28	0.73	1.40	1.16	Polyneuropath
	3.16*	2.58*	1.05	1.66*	2.10*	1.25		1.16		1.12	0.90	1.49*	1.53*	1.55*	1.18	1.16	1.15	0.63	1.12	0.97	1.15	1.37*	Myoneural
											1.01	1.00	0.86	1.31									Other degenerative
Cardio metabolic	4.54*	2.76*	1.88*	1.95*	1.37*	1.06	1.01	2.17*	1.26	1.46	1.13*	1.12*	1.17*	1.15*	1.09	1.15	1.16	1.08	1.26	0.91	1.16	1.55*	Type 2 diabetes
	0.55		1.79*	1.20	1.49*		0.96	1.26	1.08	1.03	1.27		2.11*		1.23	1.52	1.15	1.05	1.23*	0.87	1.01	1.22*	Gest diabetes
	1.11	1.41*	1.42*	1.22*	1.45*	1.08	0.97	1.31	1.01	1.29	1.15*	1.12*	1.17*	1.15*	1.17*	1.11	1.14	1.04	1.24*	1.00	1.05	1.17*	**Any diabetes**
	0.99	2.82*	1.35*	1.74*	1.42*	1.46*	1.14	1.42*	1.05	1.14	1.31*	1.23*	1.22*	1.16*	1.20*	1.27*	1.19*	1.11	1.11*	1.28*	1.17*	1.26*	Obesity
	1.67*	1.41*	1.18	1.22*	1.33*	1.09	0.98	1.30	1.11	1.41*	1.15*	1.12*	1.17*	1.15*	1.20*	1.08	1.10	1.03	1.25*	1.10	1.09	1.15	Diabetes outside preg.
	0.49*		1.13		1.11*		0.82		0.95		1.10*		1.14*		0.99		1.07		1.02	0.96	0.97	1.19	Preeclam/eclam
	0.44*		1.11		1.10*		0.75		1.02		1.10*		1.14*		0.99		1.06		1.00	0.96	0.96	1.19	Hyper in preg.
	0.80	1.60*	1.05	0.88	1.10*	1.22*	0.77	1.64	1.18	1.15	1.06*	1.02	1.04	1.02	1.00	1.00	1.09*	1.17	0.98	0.89	1.02	1.05	**Any hyper**
	2.06*	1.60*	0.94	0.88	1.19*	1.24*	1.05	1.57	1.57*	1.25	1.04	1.02	0.99	1.02	1.18	0.97	1.45*	1.18	0.86	0.87	1.20	1.01	Hyper outside preg
	1.07	1.04	0.83	1.04	1.22*	1.13	0.88	1.31	0.87	1.22	1.15*	1.14*	1.13	1.21*	1.02	1.03	1.11	1.00	1.22*	1.05	1.01	1.10	Type 1 diabetes
Birth defect	5.65*	4.25*	1.47*	1.42*	0.82	1.95	1.14	0.97	1.61	1.30	1.42				0.85	0.88	1.59	1.07	1.06	1.16	1.19	0.99	Chro/gene dis−ASD spe
			1.31	1.04	1.18	1.29	1.16	1.02	1.34	0.65	1.55		1.77		0.76	1.39*	1.16	1.28	1.18	1.00	1.10	1.13	Lip
	6.23*	4.76*	1.30*	1.38*	1.23	1.26	1.51*	1.09	1.20	1.26	1.58*	0.96	1.30	1.19	1.20	1.07	1.09	1.36*	1.16*	1.14	1.14	1.12	Other/chromos
	2.13*	2.57*	1.26*	1.23*	1.41*	0.85	1.34	1.50*	0.85	1.15	1.06	0.79	0.91	1.37	1.15	1.08	0.78	1.02	1.23*	0.99	0.98	0.96	Digestive system
	1.03	1.06	1.17	0.95	0.97	1.26	0.87	1.15	1.02	1.33	1.15	1.07	1.10	1.15	1.24	0.81	1.41*	0.85	1.17	1.08	0.93	0.97	Skin
	1.52*	1.59*	1.12*	1.14*	1.18*	1.11*	1.03	1.10	0.95	1.01	1.15*	1.10*	1.09*	1.13*	1.18*	1.04	1.03	1.07	1.05	1.06*	0.99	1.01	**Any birth defect**
	1.65*	1.84*	1.12	1.13	1.31*	0.94	1.08	1.18	0.87	0.98	1.31*	1.22	1.28	1.16	1.09	1.16	1.06	1.08	0.99	1.09	1.06	1.01	Heart
	1.83*	1.71*	1.12*	1.20*	1.27*	1.05	1.10	1.00	0.95	1.07	1.18*	1.19	1.09	0.94	1.35*	0.99	1.01	1.14	1.03	1.05	0.98	1.00	Musculoskeletal
	0.94	0.83	1.10	0.85	1.08	1.21*	1.00	0.91	1.10	1.11	1.17	1.07	0.93	1.29	1.25*	1.04	1.01	1.02	0.96	1.03	0.98	0.95	Ear
			1.09	1.25	1.21	0.73	0.72	1.89*	0.85	0.74	1.28	1.09	1.09	0.95	0.98	1.09	0.79	1.05	1.12	1.22	0.90	1.10	Respiratory
	3.69*	3.01*	1.06	1.41*	1.12	1.38	0.85	0.50		0.77	1.46	1.47	1.88*	1.67*	1.24	1.72*	0.98	1.03	1.04	0.92	1.13	1.06	CNS
	1.45	1.54*	1.04	0.91	1.18	1.59*	1.02	1.47	1.03	1.20	0.89	1.24	0.89	1.20	1.23	1.07	1.21	1.05	1.16	1.09	1.01	1.02	Urinary tract
	2.45*	1.90*	0.84	0.92	1.23	1.14	0.85	1.25	0.92	1.16	0.89	1.12	1.58*	1.71*	1.17	0.79	1.42	0.65	1.06	1.06	0.89	0.83	Eye
	1.72	1.43*	0.84	1.03	1.19*	1.08	1.61	1.04	0.44	0.89	1.13	0.91	0.90	1.05	1.08	1.00	0.90	1.09	0.89	1.02	0.96	1.00	Genital
Autoimmune	1.08	2.86*	1.81*		0.76						0.67		1.24				1.13		0.68	2.48*	1.23		Thyroiditis
	1.33	1.35	1.42*	1.13	1.11		1.52	2.02*	1.22		0.96	1.48	1.45	1.58	1.53	1.89	0.78	2.04	1.12	1.19	1.05	1.00	Celiac
		2.28*	1.33	1.03	1.66*			1.95			1.06	1.14	1.03	0.70	0.79	1.33	0.65		1.03	0.89	1.07	0.54*	Any blood
	1.41	0.98	1.33*	1.28	1.32*	1.20	1.11	1.44	0.86	1.11	1.05	0.93	1.01	1.06	1.19	1.06	1.27	1.48*	1.00	1.18	0.76*	1.06	Any connective
	1.05	0.95	1.32*	1.35	1.48*	1.46	1.34	1.48	0.87	1.07	2.25*			2.36	1.11	1.35	1.31	2.15*	0.96	1.17	0.78*	1.05	Juvenile arthritis
	0.99	1.07	1.24*	0.95	0.97	0.95	1.70*	1.14	0.95	1.04	1.10	1.03	1.13	1.02	1.17	0.89	1.27*	1.16	1.08	1.17	1.07	1.22*	Any gastrointest.
		2.36*	1.21	0.93	0.85			2.25*			0.96	1.37	1.56	0.93					1.03	0.94	1.11	0.51*	Purpura
	1.81	1.16	1.19	1.00	1.48*	1.17	1.17	2.69*	0.81		1.02	0.93	1.06	1.04	1.24	0.82	1.32	0.99	1.14	1.21	0.61*	1.28	Rheumatoid arthritis
	1.26*	1.13	1.16*	1.10	1.16*	1.06	1.12	1.39*	0.99	1.15	1.05	1.07	1.11*	1.13*	1.07	1.04	1.20*	1.01	1.11*	1.13*	0.98	1.06	**Any autoimmune**
	0.69	0.96	1.15	0.85	1.02	1.05	1.56	0.63	0.74	1.04	1.14	1.01	1.03	0.97	1.11	0.79	1.24*	1.23	0.99	1.08	1.18	1.16	Ulcerative colitis
	1.04	0.92	1.04	0.70	0.86	0.80	1.78*	0.86	1.02	1.23	1.18	1.01	1.30*	0.91	1.17	1.04	1.42*	1.04	1.16	1.28	1.05	1.34*	Crohn
	1.25	1.20	0.99	1.12	1.19*	1.11	0.79	1.26	1.00	1.14	1.06	1.14*	1.12*	1.20*	0.99	1.03	1.15	1.01	1.16	1.12	1.14	1.10	Any endocrine
	2.08*	2.40*	0.96		1.21*	1.03			1.56		1.01	1.17	1.09	1.24	0.98	1.21	1.24	0.98	1.21	1.73	1.47*		Thyrotoxicosis
	1.02	1.33	0.94	0.87	1.24	1.24	0.78		1.02	1.08	1.12	1.25*	1.12	1.03	1.02	1.19	1.08	0.63*	0.87	1.08	0.99	0.93	Any skin
	1.36	1.18	0.91	0.82	1.29*	1.23			1.40	1.21	1.12	1.24*	1.15	1.04	1.19	1.18	1.12	0.58*	0.87	1.05	0.97	0.92	Psoriasis
	1.07	1.04	0.83	1.04	1.22*	1.13	0.88	1.31	0.87	1.22	1.15*	1.14*	1.13	1.21*	1.02	1.03	1.11	1.00	1.22*	1.05	1.01	1.10	Type 1 diabetes
		0.86	0.76		1.30	1.14		2.86*	1.09	1.76	0.98	0.89	1.18*	1.02	1.12	1.11	1.06	0.99	0.54	0.54	1.04	1.10	Any nervous
					1.84						0.78	0.99	1.05	0.82				1.96	2.10		1.68	2.25	Pri adrenocortical
											1.25	1.10		0.74									Dermatopolymyositis
											1.11	0.81	0.92	0.90									Polymyalgia
											1.14	1.21	1.10	2.07*			2.19						Scleroderma
					0.97						1.28	0.95	1.05	2.27*	1.61		1.30		2.10*		1.14		Lupus erythema
					2.04						1.14	1.57	1.19	2.01*			1.87						Sjogren
					0.95	1.27					0.84	1.28	1.10	1.13	1.94*	1.18		0.66		1.14		0.83	Ankylos spondil.
					3.62*						1.02	1.31	0.72	0.68	1.94								Pernicious anem
											1.37		1.94										Hemolytic anem
					1.32	1.11			1.27		0.99	0.94	1.15	0.97	1.11	0.93	0.97	1.41	0.45		0.80	0.84	Multple sclerosis
					1.27	1.27					1.01	0.90	1.25	0.99	1.44	1.29	1.41		0.93		1.85		Guillain−Bar
											0.66		1.52	1.89*									Myasthen grav.
					1.41						1.45		1.20				1.05		1.04	1.22	1.13	1.05	Alopecia areata
		2.78*				1.77						1.78	1.00										Vitiligo
	0.88	0.83*	1.29*	1.18*	1.25*	1.12*	1.07	1.02	1.03	0.96	1.06	0.96	1.10	0.94	1.25*	1.08	1.11	1.16*	1.02	0.98	1.06	1.00	Allergies
	0.91	0.88	1.22*	1.15*	1.31*	1.10*	1.18*	1.03	1.03	0.93	1.12*	1.08	1.13*	1.01	1.18*	1.15*	1.11	1.07	1.02	1.00	1.01	1.04	Asthma

Figure 1 Legend

Hazard Ratio: the value in a cell of the heat map corresponds to the adjusted Hazard Ratio for ASD estimated from that family member type-morbidity combination. **Co-occurring condition:** the two co-occurring condition columns correspond to risk of co-occurrence of a specific diagnosis in autistic females and males. **1st degree, 2nd degree, 3rd degree**: each column corresponds to risk for ASD from a specific family member type (such as a full sister) with a specific diagnosis by degree of relatedness. 1st degree: 50% shared genes with index person. 2nd degree: 25% shared genes with index person. 3rd degree: 12.5% shared genes with index person. **Note on blank cells:** a blank cell reflects a sample size of ASD cases of <5 for the specific family member type-diagnosis combination (or <5 ASD cases with the specific co-occurring diagnosis). **Row order:** Within each major diagnosis group, the rows are ordered by diagnosis with the largest aHR (top row) to the smallest aHR (bottom row) from full sisters.

[a]**Hazard Ratio (aHR)** adjusted for sex, birth weight, gestational age, parental ages at birth; each aHR estimated using separate baseline ASD --diagnostic rates per birth year. aHRs from full/half siblings, aunts, uncles or cousins also included the number of family members of the relevant type as a covariate.

Figure 2: Percent of ASD risk estimates (aHR) by: level of risk, disorder category, in 1st, 2nd or 3rd degree relatives



Figure 3: Percent of ASD risk estimates (aHR) with a confidence interval (CI) excluding 1.0 by: disorder category, in 1st, 2nd and 3rd degree relatives.



Figure 4: Highest ASD risks (aHR) associated with a family history of specific mental and non-mental conditions



Figure 4 Legend

The focus of Figure 4 is to show the specific condition in a specific 1st degree family member type for which the aHR for ASD exceeded 3.0. For completeness, all aHRs for 1st degree family members with the specific condition are included in the Figure even though some of the aHRs are less than 3.0. Within each diagnosis, the rows are ordered by the 1st degree family member with the largest aHR (top row) to the smallest aHR (bottom row). A missing estimate (missing row) reflects a sample size of ASD persons of <5 for the specific family member type-diagnosis combination.

Figure 5. Significant aHR[a] for ASD of highest magnitude by diagnosis associated with affected 1st, 2nd and 3rd degree relatives





[a]aHR: Hazard Ratio adjusted for sex, birth weight, gestational age, parental ages at birth and labeled significant if 95% confidence interval excluded 1.0. Each aHR estimated using separate baseline ASD diagnostic rates per birth year. aHRs from full/half siblings, aunts, uncles or cousins also included the number of family members of the relevant type as a covariate. Vertical lines are 95% confidence limits.

/

Table 1. Characteristics of persons with and without autism spectrum disorder (ASD) in study cohort

	No ASD		ASD	
	n=1,670,391		*n=26,840*	
	n	%	n	%
Male	851,349	51.0	19,900	74.1
Intellectual disability: Yes	7,697	0.5	3,342	12.5
Gestational age (weeks)				
≤36	96,874	5.9	2,040	7.7
37-40	1,111,458	67.6	17,467	65.6
41+	436,989	26.6	7,112	26.7
Maternal age (36+ years)	211,979	12.7	3,797	14.1
Paternal age (36+ years)	430,612	25.8	7,654	28.5
Birth weight (grams)				
≤2500	88,542	5.3	1,810	6.8
2501-3000	210,534	12.7	3,448	12.9
3001-4000	1,089,957	65.6	16,506	61.8
4001+	273,317	16.4	4,929	18.5

Birth year	No ASD		ASD			No ASD		ASD	
	n=1,670,391		*n=26,840*			*n=1,670,391*		*n=26,840*	
	n	%	n	%		n	%	n	%
1980	51,048	3.1	153	0.6	**1996**	54,272	3.2	1,279	4.8
1981	47,172	2.8	172	0.6	**1997**	53,666	3.2	1,416	5.3
1982	46,860	2.8	236	0.9	**1998**	52,138	3.1	1,470	5.5
1983	45,259	2.7	248	0.9	**1999**	517,570	3.1	1,546	5.8
1984	45,873	2.7	292	1.1	**2000**	51,834	3.1	1,668	6.2
1985	47,435	2.8	342	1.3	**2001**	50,275	3.0	1,496	5.6
1986	48,334	2.9	353	1.3	**2002**	49,391	3.0	1,361	5.1
1987	48,578	2.9	399	1.5	**2003**	50,024	3.0	1,277	4.8
1988	50,616	3.0	500	1.9	**2004**	50,572	3.0	1,158	4.3
1989	52,444	3.1	583	2.2	**2005**	50,565	3.0	1,055	3.9
1990	53,925	3.2	692	2.6	**2006**	51,207	3.1	985	3.7
1991	53,912	3.2	788	2.9	**2007**	50,321	3.0	857	3.2
1992	56,527	3.4	877	3.3	**2008**	50,788	3.0	656	2.4
1993	55,769	3.3	970	3.6	**2009**	48,470	2.9	561	2.1
1994	57,302	3.4	1,213	4.5	**2010**	48,593	2.9	503	1.9
1995	57,101	3.4	1,189	4.4	**2011**	44,783	2.7	345	1.3
					2012	43,579	2.6	200	0.7